BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33677616)

  • 21. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS 80).
    Jürgens H; Beron G; Winkler K
    J Cancer Res Clin Oncol; 1983; 106 Suppl():14-8. PubMed ID: 6350313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
    Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
    Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
    Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
    Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
    Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
    Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
    Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
    Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
    J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
    Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
    J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
    Borsi JD; Schuler D; Moe PJ
    Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
    Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
    Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
    Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
    Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concepts in use of high-dose methotrexate therapy.
    Treon SP; Chabner BA
    Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study.
    Carvalho Pedrosa D; Macedo de Oliveira Neves F; Cavalcante Meneses G; Pinheiro Gomes Wirtzbiki G; da Costa Moraes CA; Costa Martins AM; Braga Libório A
    Pediatr Nephrol; 2015 Dec; 30(12):2207-13. PubMed ID: 26248472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.
    Gallais F; Oberic L; Faguer S; Tavitian S; Lafont T; Marsili S; Brice A; Chatelut E; Puisset F
    Ther Drug Monit; 2021 Jun; 43(3):408-415. PubMed ID: 32925658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
    Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
    Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
    Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
    Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.